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Differential expression of miR-17B92 identiﬁes BCL2 as a
therapeutic target in BCR-ABL-positive B-lineage acute
lymphoblastic leukemia
M Scherr1, A Elder2,7, K Battmer1,7, D Barzan1,7, S Bomken2,3, M Ricke-Hoch4, A Schro¨der5, L Venturini1, HJ Blair2, J Vormoor2,3,
O Ottmann6, A Ganser1, A Pich5, D Hilfiker-Kleiner4, O Heidenreich2 and M Eder1
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk
disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17B92, is regulated by BCR-ABL
fusion in chronic myeloid leukaemia, we investigated its role in BCR-ABL translocated ALL. miR-17B92-encoded miRNAs were
signiﬁcantly less abundant in BCR-ABL-positive as compared to -negative ALL-cells and overexpression of miR-17B19b triggered
apoptosis in a BCR-ABL-dependent manner. Stable isotope labelling of amino acids in culture (SILAC) followed by liquid
chromatography and mass spectroscopy (LC-MS) identiﬁed several apoptosis-related proteins including Bcl2 as potential targets of
miR-17B19b. We validated Bcl2 as a direct target of this miRNA cluster in mice and humans, and, similar to miR-17B19b
overexpression, Bcl2-speciﬁc RNAi strongly induced apoptosis in BCR-ABL-positive cells. Furthermore, BCR-ABL-positive human ALL
cell lines were more sensitive to pharmacological BCL2 inhibition than negative ones. Finally, in a xenograft model using patient-
derived leukaemic blasts, real-time, in vivo imaging conﬁrmed pharmacological inhibition of BCL2 as a new therapeutic strategy in
BCR-ABL-positive ALL. These data demonstrate the role of miR-17B92 in regulation of apoptosis, and identify BCL2 as a therapeutic
target of particular relevance in BCR-ABL-positive ALL.
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INTRODUCTION
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease
with multiple, prognostically relevant genetic aberrations. In
adults, 30–40% of patients with precursor-B ALL express the
BCR-ABL oncogene as the result of the Philadelphia-translocation
t(9;22)(q34;q11) deﬁning a very high-risk proﬁle.1,2 The BCR-ABL
oncoprotein is a constitutively active tyrosine kinase involved in
hematopoietic cell transformation. Inhibition of its enzymatic
activity by speciﬁc tyrosine kinase inhibitors has substantially
improved and fundamentally changed the treatment of chronic
myeloid leukaemia and enhanced cure rates in BCR-ABL-positive
childhood ALL.3,4 However, treatment of adult BCR-ABL-positive
ALL remains challenging. The historically poor outcome of Phþ
ALL patients has been substantially improved by combining
tyrosine kinase inhibitors with induction and post-remission
chemotherapy, resulting in higher remission rates and therefore
a greater proportion of patients undergoing allogeneic
hematopoietic stem cell transplantation (SCT).5–7 At present,
myeloablative conditioning followed by allogeneic SCT remains
the only established curative therapy, with several prospective
trials showing an overall survival of 30–65%.8–10 Despite these
advances, high transplant-associated mortality and relapse remain
considerable obstacles, and the majority of elderly patients are not
considered suitable candidates for allogeneic SCT, resulting in a
still dismal long-term outcome.6 This has not been altered
dramatically by the recent availability of more potent second
generation tyrosine kinase inhibitors,11 and most likely involves
mechanisms of resistance distinct from BCR-ABL tyrosine kinase
domain mutations.12 Therefore, it is important to develop new
targeted agents alongside tyrosine kinase inhibitors to improve
survival and reduce morbidity in those patients currently able to
undergo allogeneic SCT as well as to offer improved
pharmacotherapy for patients not suitable for SCT.
miRNAs are a class of small non-coding RNAs involved
in posttranscriptional control of gene expression. Upon
processing, miRNAs are incorporated in an effector complex
RNA induced silencing complex (RISC) which is recruited to at
least partially complementary sites in target-gene mRNAs.
Individual miRNAs can bind to multiple mRNAs with
differential effects on gene expression of multiple targets.
We hypothesised that miRNAs may be used to identify
potential leukaemia-relevant therapeutic targets if they are
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differentially expressed in tumour cells and if they are linked to
disease-relevant phenotypes.
The polycistronic microRNA cluster miR-17B92 encodes
miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.13
Notably, miR-17B92-deﬁcient mice suffer signiﬁcant develop-
mental cardiac defects and lung hypoplasia though
interrogation of haematopoiesis identiﬁed isolated defects in
B-lineage development.14 Moreover, we observed a high
expression of miR-17B92 in adult heart and in postnatal
cardiomyocytes. miR-17B92 has also been strongly implicated
in both solid and haematopoietic malignancies.15,16 Of these, the
ﬁrst and now best-studied group is the mature B-lymphoid
malignancies.17
Conditional knockout of the cluster-revealed modulation of
apoptosis as the predominant mechanism of action of
miR-17B92.18 In normal lymphopoiesis, loss of miR-17B92
results in upregulation of Bim (Bcl2l11) and increased apoptosis,
inhibiting the pro-B to pre-B transition.14 Conversely, moderate
overexpression of miR-17B92 causes a reduction in Bim and Pten
expression, resulting in lymphoproliferation and autoimmune
disease.19 Dissection of the miR-17B92 cluster has demonstrated
that miR-19 is both necessary and sufﬁcient to abrogate apoptosis,
at least in Myc-mediated lymphomagenesis most likely by
repression of PTEN and BIM.18,20
Based on our previous work in chronic myeloid leukaemia,21 we
ﬁrst analysed miR-17B92 expression in ALL and observed a
signiﬁcantly lower expression in ALL as compared to normal
CD34þ cells with further reduction in BCR-ABL-positive as
compared to -negative ALL cells. We next over-expressed the
miR-17B92 derivative miR-17B19b in an inducible model of
BCR-ABL-positive ALL, thereby identifying impaired apoptosis
as a key determinant of reduced miR-17B92 function in this
disease setting. Quantitative proteome-wide expression analysis
and alignment of miR-17B19b seed regions identiﬁed multiple
apoptosis regulators as being downregulated by miR-17B19b-
overexpression. From these, BCL2 was validated as a direct target
of the miR-17 and miR-18a, and BCL2 knockdown resulted in
strong induction of apoptosis in BCR-ABL-positive, but not
BCR-ABL-negative ALL cells. Accordingly, BCR-ABL-positive cells
also demonstrated a selective sensitivity to the BCL2 inhibitor
ABT-737 in vitro. Finally, we demonstrated the sensitivity of
BCR-ABL-positive ALL to ABT-737 in a real-time in vivo validation
assay using patient-derived primary ALL cells transduced with
luciferase. This study identiﬁes BCL2 as a potential therapeutic
target in BCR-ABL-positive ALL.
MATERIALS AND METHODS
Patient material
BM and PB samples were collected from 13 and 14 newly diagnosed
BCR-ABL-positive and -negative B-lineage ALL, respectively (X60% blasts).
BM-derived CD34þ cells from four healthy volunteers served as controls.
The study was approved by the Ethics Committee of the University of
Frankfurt.
Patient-derived material used for mouse transplantation was collected
as part of the initial diagnostic investigation of patients. It was collected,
stored and used with written informed consent according to approvals
given by the local institutional review boards and the Declaration of
Helsinki. Samples were retrieved from Newcastle Haematological BioBank
under the generic BioBank approval given by the Newcastle & North
Tyneside Ethics Committee (REC reference number: 07/H0906/109).
SILAC, LC-MS and data processing
TonB cells were cultured with either isotopically labelled Lysine
(13C6-
15N2-Lys) and Arginine (
13C6-
15N4-Arg) (heavy state), Lysine (
2H4-Lys)
and Arginine (13C6-Arg) (medium state) or natural Lysine and Arginine
(light state). Three biological replicates were prepared with all three
Figure 1. BCR-ABLþ ALL samples have a reduced expression of miR-17B92. Differential expression of miR-17B92-encoded miRNAs in
primary BCR-ABL-positive and BCR-ABL-negative B-lineage ALL patient samples and normal CD34þ cells as determined by miR-qRT-PCR.
Data are presented as DCT of miR-17B92 expression in patient samples, with higher DCTs indicating lower expression. **P-value o0.001;
***P-value o0.0001.
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labelling states, light, medium and heavy, included as described recently.22
Cell lysates were separated by SDS-PAGE followed by gel slicing, extraction
and trypsin digestion. Peptide samples were separated and fragmented
with a nano-ﬂow ultra-high pressure liquid chromatography system (RSLC,
Thermo Scientiﬁc, Waltham, MA, USA) coupled online to a Nano Spray Flex
Ion Source II (Thermo Scientiﬁc) of an LTQ-Orbitrap Velos mass
spectrometer. Fragment ion mass spectra were recorded in the LTQ part
of the mass spectrometer at a normal scan rate and stored as centroid m/z
value and intensity pairs. Raw data were processed with the MaxQuant
proteomics software (MaxQuant, Martinsried, Germany) suite version
1.1.1.36 for identiﬁcation and quantiﬁcation of proteins as described.
Peptides and proteins were identiﬁed with the implemented Andromeda
search engine version 1.1.0.36 and the human entries of the IPI protein
data base (v. 3.73).
Immunoprecipitation of human argonaute 2 complexes using the
RIP-ChIP kit
Lentiviral supernatants expressing miR-17B19b and control vector SIEW
were used to transduce B1 106 293 cells with an MOI of B2.
Figure 2. miR-17B19b reduces proliferation and increases apoptosis in BCR-ABLþ cells (a) Proliferation kinetics of TonB cells expressing
miR-17B19b either in the presence of IL-3 (left) or doxycycline (right) as determined by trypan blue exclusion. Values are expressed as
means±s.d. (b) Induction of apoptosis in TonB cells expressing miR-17B19b (lower panels) or control vector SIEW (upper panels) in the
presence of IL-3 (left) or doxycycline (right) as determined by PI staining. The percentage of apoptotic cells (subG1 phase) is shown.
(c) Cleavage of Caspase 3 in TonB cells expressing control vector SIEW (lanes 1–3) or the miR-17B19b polycistron (lanes 4–5) in the presence
of IL-3 (lanes 2 and 4) or doxycycline (lanes 3 and 5). Whole-cell lysates were subjected to western blotting to determine cleavage of caspase 3
24 h after induction of BCR-ABL by doxycycline.
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microRNA:mRNA immunoprecipitation was performed using the Magna
RIP RNA-Binding Immunoprecipitation kit (Millipore, Billerica, MA, USA)
following the manufacturer’s protocol. A total of 5 106 cells were taken
for each replicate and washed in phosphate buffered saline, prior to lysis in
100ml complete RIP-lysis buffer and overnight incubation with magnetic
beads conjugated with an anti-AGO2/eIF2C2 antibody (Abcam, Cambridge,
UK) or control normal mouse IgG (Millipore) at 10 1C with rotation.
Coimmunoprecipitated RNA, including miRNA:mRNA complexes, was
subjected to qRT-PCR and miR-qRT-PCR as described before.
ABT-737 treatment in mouse xenotransplantation studies
Primograft material was lentivirally transduced and intrafemorally trans-
planted into NSG mice as described previously.23,24 Mice were imaged using
an IVIS Spectrum pre-clinical imaging system (Perkin Elmer). Mice were
injected with either vehicle control or ABT-737 (50mg/kg/day) for a total of
30 days (5 days on, 2 days off). Mice were kept until they exhibited clinical
symptoms that necessitated humane killing. Kaplan–Meier curves were
plotted and analysed using GraphPad Prism software (GraphPad, San Diego,
CA, USA), with signiﬁcance assessed using a Log-rank (Mantel–Cox) test. All
work was conducted in accordance with the UK Home Ofﬁce Project Licence
PPL60/3846.
RESULTS
miR-17B92 is downregulated in BCR-ABL-positive human ALL
samples
We previously demonstrated an increased miR-17B92 expression
in chronic phase chronic myeloid leukaemia CD34þ cells,
compared to normal CD34þ cells from healthy donors.14 Based
on this, we analysed expression of miR-17B92 encoded miRNAs
in 14 BCR-ABL-negative and 13 BCR-ABL-positive ALL samples, as
well as normal CD34þ cells, using miR-qRT-PCR. To our surprise,
all individual miR-17B92 miRNAs were less abundant in ALL as
compared to normal CD34þ cells (Figure 1). Furthermore, BCR-
ABL-positive ALL samples exhibited a 9- to 32-fold reduction in
miRNA expression compared to BCR-ABL-negative ALL cells, with
the exception of miR-92 which was therefore not further analysed.
The miRNA polycistron is differentially expressed and induces
apoptosis in a BCR-ABL-speciﬁc manner
To investigate whether differential miR-17B92 expression is
controlled by BCR-ABL, we used an inducible murine model of
BCR-ABL expression. TonB cells are derived from BaF3, a B-lymphoid
Figure 3. miR-17B19b targets several apoptosis-related proteins. (a) Downregulated proteins involved in the regulation of apoptosis. Reduced
protein expression (bold) was validated by immunoblotting as shown in (b). 1Gene ID according to NCBI (http://www.ncbi.nlm.nih.gov/); 2mean
value of n¼ 3 experiments, *n¼ 2 experiments; 3t-test; two-tailed; paired. (b) Western blotting showing Granzyme B (Gzmb), Adseverin (Scin), Bcl2,
DnaJB6, Aif (Aifm-1), Sequestosome-1 (Sqstm1), Sialophorin (Spn) and Shp-1 (Ptpn6) protein expression in TonB cells lentivirally transduced with
control vector SIEW (left) or miR-17B19b (right). Relative expression levels were normalised to b-actin, which served as a loading control.
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cell line, and have been modiﬁed to conditionally express BCR-ABL
upon addition of doxycycline.25 In this setting, expression of
BCR-ABL was associated with a 2.3–3.3-fold reduction in expression
of miR-17, -18a and -19a, in agreement with our ﬁndings in primary
ALL samples (Supplementary Figure 1). These results suggested
that miR-17B92 miRNAs could have previously undiscovered
anti-oncogenic functions under certain circumstances.
TonB cells are dependent on interleukin-3 (IL-3) for survival and
growth; induction of BCR-ABL allows cytokine-independent
proliferation, making them an ideal system to study miR-17B92
function in the context of BCR-ABL. As miR-92a expression was
unchanged between BCR-ABL-positive and -negative ALL cells
(Figure 1), we transduced TonB cells to overexpress miR-17B19b,
a derivative of miR-17B92 suitable for transgenic expression.21,26
miRNA expression was increased between 5- and 16-fold upon
transduction (miR-17 5.2-fold, miR-18a 2.1-fold, miR-19a 9-fold,
miR-19b 10.6-fold, and miR-20a 15.8-fold). Proliferation of
TonB cells grown in the presence of IL-3 was only slightly
reduced by transgenic miR-17B19b expression as compared to
controls (SIEW) (Figure 2a, left). In contrast, BCR-ABL-mediated cell
proliferation was strongly inhibited by miR-17B19b (Figure 2a,
right).
To study the impact of miR-17B19b on cell cycle regulation
and apoptosis, transgenic TonB cells were analysed for DNA
content in the presence and absence of BCR-ABL. Whereas cell
cycling was only marginally affected, apoptosis was markedly
enhanced by overexpression of miR-17B19b following induction
of BCR-ABL. Transgenic expression of miR-17B19b increased the
subG1 fraction from 33 to 67% compared to vector controls
(Figure 2b, right), whereas in BCR-ABL-negative cells it remained
almost unchanged (7 and 11%, respectively, Figure 2b, left). In
agreement with the DNA content analysis, increased cleavage of
caspase 3 was observed in BCR-ABL expressing as compared to IL-3
supplemented cell cultures (Figure 2c, lanes 2 and 3). Over-
expression of miR-17B19b also led to a further increase in
caspase 3 cleavage in BCR-ABL expressing cells (Figure 2c, lanes 3
and 5), but not in cells grown in the presence of IL-3 (Figure 2c,
lanes 2 and 4). Together, these data demonstrate that miR-
17B19b decreases cell proliferation and markedly increases
apoptosis in a BCR-ABL-speciﬁc manner.
Figure 4. miR-17B19b directly targets BCL2. (a) Bar graph of luciferase activity in stably transfected NIH3T3/S-17–19b-IEW cells co-transfected
with a psiCHECK empty vector (psiCHECK-ctrl) or psiCHECK vector harbouring either the candidate wildtype or mutated (mut) miR-17 or miR-
18a-binding sites in the murine Bcl2 transcript. *P-value o0.05. (b and c) RNA-binding protein immunoprecipitation (RIP) assays for AGO2
complexes in 293 cells transduced with lentiviral vectors encoding miR-17B19b or control vector SIEW. Levels of miR-17, miR-18a and miR-
20a (b) and BCL2 mRNA (c) were quantified by qRT-PCR. Graphs show expression levels in miR-17B19b transduced cells relative to
untransduced cells for both the input (left) and AGO2 immunoprecipitated fraction (right). All data are means±s.d. (n¼ 3). (d) Western blots
depicting protein levels of BCL2 after lentiviral transduction of BV173 cells with antagomirs directed against miR-17, miR-18a, miR-20a, or
control miR alone.
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miR-17B19b targets regulators of apoptosis
Given that miR-17B19b overexpression was a driver of cell death
in TonB cells in a BCR-ABL-speciﬁc manner, we hypothesised that
identifying key targets of the cluster could provide novel
therapeutic opportunities in BCR-ABL-positive ALL. miRNAs
predominantly affect protein expression, so we initially used a
stable isotope labelling in cell culture (SILAC)-based approach to
identify miR-17B19b- and miR-20a-regulated proteins. miR-20a
overexpression showed similar, but weaker, effects to
miR-17B19b in preliminary experiments (data not shown). TonB
cells metabolically labelled with heavy, medium, or light isotope
lysine and arginine versions were lentivirally transduced with
miR-17B19b, miR-20a, or a control vector (SIEW). Cells were
cultured with IL-3 and differential protein expression was analysed
by quantitative proteomics using liquid chromatography mass
spectrometry (LC-MS). Upon lentiviral transduction, miR-17B19b
miRNA expression was increased between 3- and 12-fold as
compared to controls (Supplementary Figure 2A). In total, we
identiﬁed 3962 proteins from TonB cell lysates and were able to
determine the abundance of 3541 of these proteins under all
three labelling conditions (Supplementary Table 1A). The correla-
tion between the three labelling conditions was high, with r2
between 0.54 and 0.65 (Supplementary Figure 2B). In total, 84
proteins were regulated more than 1.7-fold by miR-17B19b, with
31 exhibiting higher abundance and 53 exhibiting lower
abundance in miR-17B19b transgenic TonB cells. Protein
abundance was only slightly affected in miR-20a cells and thus,
respective proteins were not further analysed.
We next categorised the 53 low abundance proteins into
functional groups using GeneCoDis 2.0. Gene enrichment analysis
revealed 269 hits in 102 different gene ontology groups
(Supplementary Figure 2C). In keeping with the enriched subG1
fraction and caspase 3 cleavage pattern, ‘regulation of apoptosis’
(GO: 0042981) contained eight genes (Figure 3a), and was the
largest single group of all identiﬁed gene ontologies. These
ﬁndings were conﬁrmed by the KEGG pathway analysis
(Supplementary Table 1B). We further validated the apoptosis-
related candidate targets by western blotting. As shown in
Figure 3b, protein expression of Adseverin (Scin), Bcl2, Sialophorin
(Spn), Aifm-1 (Aif), Sequestosome-1 (Sqstm1) and Shp-1 (Ptpn6)
was reduced in the presence of miR-17B19b (from 0.2- to
0.65-fold), whereas protein levels of Granzyme B (Gzmb) and
DnaJB6 remained unchanged.
These data point to a direct role for miR-17B19b encoded
miRNAs in the regulation of apoptosis in BCR-ABL-positive ALL.
Overcoming apoptosis is key to leukemogenesis, and agents
targeting cell death, notably corticosteroids, has a major role in
the therapy of ALL. BCL2 is a well-established inhibitor of
mitochondrial apoptotic pathways, and has emerged as a
potential therapeutic target in both leukaemias and solid
tumours.27,28 We therefore decided to focus on the proteins
involved in regulation of apoptosis and on BCL2 in particular.
miR-17B19b suppresses expression of Bcl2
We next analysed the presence of putative miR-17B92-binding
sites (seed matches) within the target mRNAs. As miRNAs binding
is not restricted to exact reverse complement seed sequences
within the 30-untranslated region (UTR)28,29 we used the miRNA
target prediction programme RNA22 based on earlier reports of its
low false prediction rate and ability to discover noncanonical
targets.29–32 As shown in Figure 3a, all targets analysed have at
least two miRNA-binding sites for the miR-17B19b cluster.
Notably, six binding sites for miR-17B19b miRNAs (three sites
for miR-18a, two sites for miR-17 and one site for miR-20a) are
located within the 50UTR and CDS of murine Bcl2 (Supplementary
Figure 3A). In human BCL2, we identiﬁed 13 binding sites for miR-
17B19b miRNAs (ﬁve sites for miR-17, six sites for miR-18a and
two sites for miR-20a) located within the CDS and 30UTR
(Supplementary Figure 3B).
To verify that Bcl2 is a direct target of miR-17B19b miRNAs,
we transfected luciferase reporter constructs containing murine
Bcl2 sequences into miR-17B19b overexpressing NIH3T3 cells.
As shown in Figure 4a, miR-17B19b signiﬁcantly repressed
luciferase activity for the wildtype but not for mutated miR-17
and miR-18a-binding sites in the murine Bcl2 50UTR. The CDS-
binding sites showed no effect on luciferase activity (data not
shown). These data demonstrate that the expression of murine
Bcl2 is directly regulated by miR-17B19b through miRNA binding
within the 50-UTR.
Having conﬁrmed murine Bcl2 as a target of miR-17B19b, we
next analysed speciﬁc targeting of the human BCL2 transcript by
the cluster. We used qRT-PCR to investigate the association of
BCL2 mRNA with AGO2, the catalytic component of RISC in
miR-17B19b overexpressing human 293 cells. Assessment of
miR-17B19b levels following transduction conﬁrmed overexpres-
sion and AGO2 association of all three miRNAs (Figure 4b).
Whereas levels of BCL2 mRNA in the input fraction were
unchanged following miR-17B19b overexpression, anti-AGO2
immunoprecipitates speciﬁcally pulled down 3.2-fold more
BCL2 mRNA as compared to controls (Figure 4c). This shows that
miR-17B19b overexpression results in increased binding of BCL2
mRNA to AGO2 demonstrating speciﬁc targeting of BCL2 mRNA
by miR-17B19b miRNAs. We further conﬁrmed this by a
complementary approach using lentiviral overexpression of
antagomirs against miR-17, miR-18 and miR-20a in the human
BCR-ABL-positive BV173 cell line.33 All antagomirs increased
BCL2 expression by approximately 20% (Figure 4d). Together,
these data demonstrate direct and functional miRNA binding of
miR-17B19b members namely miR-17/miR-20a and miR-18a
to human BCL2 mRNA. They also strongly suggested that
miR-17B19b mediated repression of Bcl2 could contribute to
the pro-apoptotic effects of the cluster in the context of BCR-ABL.
Repression of murine and human Bcl2 expression mimics miR-
17B19b overexpression
To study the functional contribution of Bcl2 to the miR-17B19b-
induced phenotype, we lentivirally transduced TonB cells to
express either anti-Bcl2- or control shRNA. Anti-Bcl2 shRNA
reduced Bcl2 protein expression by B70% – a similar level to
overexpression of miR-17B19b (B80%) (Figure 5a). In IL-3
supplemented cultures, expression of Bcl2 shRNA inhibited cell
proliferation by about 25% compared to controls (Figure 5b, left),
whereas BCR-ABL driven cell proliferation was inhibited by about
75% (Figure 5b, right) suggesting a particular requirement for Bcl2
in BCR-ABL expressing cells.
We next analysed the functional effects of miR-17B19b
overexpression in human BCR-ABL-positive ALL cell lines. As
shown in Figure 5c, lentiviral transduction of miR-17B19b into the
human BCR-ABL-positive cell lines Tom-1, BV173 and SupB15
inhibited cell proliferation by 40–55% as compared to controls
(Figure 5c, left). In contrast, transduction of the BCR-ABL-negative
ALL cell lines REH, Nalm-6, and 697 with miR-17B19b had no, or
only minor, inhibitory effects on cell proliferation (Figure 5c, right).
Expression of miR-17B19b reduced BCL2 protein expression in
BCR-ABL-positive ALL cell lines by 30–70% (Supplementary
Figure 4A).
Cell lines were subsequently transduced with either anti-BCL2
or control shRNA. Anti-BCL2 shRNA substantially reduced BCL2
mRNA expression in all cell lines (Supplementary Figure 4B).
In BCR-ABL-positive Tom-1, BV173 and SupB15 cells, expression of
BCL2 shRNA inhibited cell proliferation (Figure 5d, left), whereas
reduction of BCL2 mRNA expression in BCR-ABL-negative Nalm-6,
REH and 697 cells did not substantially inhibit cell proliferation.
(Figure 5d, right). Efﬁcient downregulation of BCL2 protein in
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SupB15 cells by lentivirally mediated overexpression of both
miR-17B19b and anti-BCL2 shRNA was further conﬁrmed by
ﬂuorescence microscopy demonstrating co-localisation of BCL2
(red) and the mitochondrial protein COX4 (green) (Figure 5e).
Together, these results demonstrate a speciﬁc role for BCL2 in the
proliferation of human BCR-ABL-positive ALL cells and suggest
that the miR-17B92 cluster suppresses BCL2 in BCR-ABL-positive
cells.
The BCL2 inhibitor ABT-737 speciﬁcally inhibits BCR-ABL-positive
lymphoid cell lines
The importance of BCL2 for the proliferation of BCR-ABL-positive
cell lines suggested that BCL2 could be a highly promising novel
therapeutic target. To assess the potential of pharmacological
BCL2 inhibition in B-lineage ALL, BCR-ABL-positive and -negative
ALL cell lines were treated with the BCL2 inhibitor ABT-737 for
24 h, prior to assessment of cell death. ABT-737 inhibited
proliferation of the BCR-ABL-positive cell lines Tom-1, BV173 and
SupB15 with IC50s of 0.054 mM, 0.15 mM and 0.030 mM, respectively
(Figure 6, left). In contrast, the IC50 for ABT-737 was substantially
higher in two out of three BCR-ABL-negative cell lines 697, Nalm-6
and REH with IC50s of 0.066 mM, 2.2 mM, and 7.8 mM, respectively
(Figure 6, right).
Effects of ABT-737 and Imatinib in BCR-ABL-positive ALL cells
Having demonstrated speciﬁc effects of pharmacological BCL2
inhibition in BCR-ABL-positive cells, we compared ABT-737 with
imatinib in both a cell line (BV173) and a patient-derived sample.
For the latter, we used primary BCR-ABL-positive precursor-B cell
ALL blasts, which had been passaged through NOD/LtSz-scid
IL-2Rg null (NSG) mice (primograft, designated L4951 cells).23 Cells
were incubated with either drug or vehicle control and the
number of viable cells was determined over time. As shown in
Figures 7a and b, ABT-737 induced a more rapid decline of viable
cell numbers than imatinib in both BV173 and L4951 cells.
Interestingly, immunoblotting revealed a rapid decrease in
BCL2 protein expression following ABT-737 treatment in both
primograft material and BV173 cells (Figures 7c and d). A rapid
decline of BCL2 protein was also observed in SupB15 cells as early
as 6 h after addition of ABT-737 (Supplementary Figure 5A).
Imatinib treatment did not affect the BCL2 protein expression and
this depletion was not observed in BCR-ABL-negative ALL cell
lines (Figure 7e). Furthermore, after ABT-737 but not imatinib
treatment, a delayed increase in expression of miR-17B92
encoded miRNAs (starting at approximately 24 h after addition
of ABT-737, Figure 7f, Supplementary Figure 5B) has been
observed. These data demonstrate different mechanisms of action
for ABT-737 and imatinib in BCR-ABL-positive ALL cells and
suggest a role for miR-17B92 encoded miRNAs in BCL2-mediated
apoptotic pathways in these cells. They also suggest that
inhibition of BCL2 by ABT-737 results in perturbations in wider
signalling networks that leads to expression changes in both miR-
17B92 and BCL2 protein.
BCL2 inhibition inhibits tumour xenograft growth in vivo
Finally, we examined the therapeutic potential of BCL2 inhibition
by evaluating the ability of ABT-737 to inhibit growth of primary
leukaemia cells in vivo. We developed a murine xenotransplanta-
tion assay of patient-derived primary leukaemic cells, which allows
for real-time monitoring of drug therapies by bioluminescent
imaging.24 Primograft L4951 cells were lentivirally transduced with
a luciferase-expressing vector (pSLIEW, transduction efﬁciency
B40%) and transplanted intrafemorally into NSG mice.
Following successful engraftment determined by bioluminescent
imaging, mice were injected intraperitoneally with either ABT-737
(50mg/kg/day) or vehicle control for a total of 30 treatments.
Mice treated with ABT-737 showed a substantially reduced
dissemination of luciferase-expressing leukaemic blast cells over
the treatment period, represented by a decrease in total photon
ﬂux emitted (Figures 8a and b, Supplementary Figure 6).
In addition, ABT-737 treatment signiﬁcantly lengthened the time
before the mice developed clinical symptoms that necessitated
humane killing, with median survival increased from 151 to 190
days (P¼ 0.0004) (Figure 8c). Termination of ABT-737 treatment
was followed by an increase in photon ﬂux, demonstrating that
disease control during the treatment period was being mediated
by ABT-737. These results demonstrate that BCL2 inhibition is a
viable treatment strategy for BCR-ABL-positive ALL in vivo. They
also conﬁrm the potential of our model to assess novel drug
therapies on patient-derived malignant cells in an in vivo setting.
DISCUSSION
In a search for new therapeutic strategies in BCR-ABL-positive ALL,
we identiﬁed targets of miRNAs with differential expression and
function in these cells. As we have shown upregulation of
Figure 6. Pharmacological inhibition of BCL2 is effective in BCR-ABLþ cell lines. Cell death was assessed by uptake of propidium iodide (PI)
after treatment with increasing concentrations of ABT-737 in BCR-ABL-positive cell lines (Tom-1, SupB15, BV173, left) and BCR-ABL-negative
cell lines (Nalm-6, REH, 697, right) for 24 h. IC50 values were calculated using GraphPad Prism software.
Figure 5. Repression of Bcl2 mimics miR-17B19b overexpression in human and mouse. (a) Western blots of Bcl2 after lentiviral transduction
of TonB cells with anti-Bcl2 shRNA or control shRNA. (b) Proliferation kinetics of TonB cells expressing anti-Bcl2 shRNA or control vector either
in the presence of IL-3 (left) or doxycycline (right) as determined by trypan blue exclusion. (c) Proliferation kinetics of BCR-ABL-positive cell
lines Tom-1, SupB15, and BV173 (left) and of BCR-ABL-negative cell lines Nalm-6, REH and 697 (right) expressing miR-17B19b or control vector
using trypan blue exclusion. (d) Proliferation kinetics of BCR-ABL-positive cell lines Tom-1, SupB15, or BV173 (left) and of BCR-ABL-negative cell
lines Nalm-6, REH, or 697 (right) after transduction with anti-BCL2 shRNA or ctrl-shRNA using trypan blue exclusion. All values were expressed
as means±s.d. (e) Fluorescence microscopy of SupB15 cells transduced with control vector (top), miR-17B19b (middle), or anti-BCL2 shRNA
(down) of BCL2 protein (red) or the mitochondrial marker COX IV (green). Cells were counterstained with DAPI (blue), scale bar: 20 mm.
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the oncomir miR-17B92 in chronic phase chronic myeloid
leukaemia,21 we investigated the role of this cluster in BCR-ABL-
positive ALL. To our surprise, patient samples showed signiﬁcantly
lower expression of mature miR-17B92 elements in BCR-ABL-
positive ALL than in either BCR-ABL-negative ALL or normal
CD34þ cells. Furthermore, the TonB model of inducible BCR-ABL
expression on a murine B-lymphoid precursor background
demonstrated a signiﬁcant reduction in mature miR-17B92
expression following induction of BCR-ABL, conﬁrming the
speciﬁcity of this ﬁnding for BCR-ABL-positive ALL.
Overexpression of the miR-17B92 derivative miR-17B19b
resulted in reduced proliferation and notably a substantial pro-
apoptotic effect, with a signiﬁcantly enriched subG1 population
and concomitant cleavage of caspase 3. This effect is surprising, as
Figure 7. ABT-737 is more potent than Imatinib in cell lines and primary material. BV173 cells (a) and L4951 primograft cells (b) were treated
with ABT-737 (0.1 mM), Imatinib (1 mM) or DMSO control and cell viability was assessed by PI uptake. (c and d) Western blots depicting protein
levels of BCL2 in BCR-ABL-positive L4951 and BV173 cells after treatment with Imatinib (1 mM) or ABT-737 (1 mM) at the indicated time points.
(e) Western blots depicting protein levels of BCL2 in BCR-ABL-negative 697 and Nalm-6 cells after treatment with ABT-737 at indicated time
points. (f ) The levels of miR-17, miR-18a and miR-19 following ABT-737 treatment were determined by miR-qRT-PCR. Graphs show fold change
compared to DMSO controls.
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previous studies of miR-17B92 have shown direct regulation of
‘pro-apoptotic’ molecules Bim and Pten in normal lympho-
poiesis,14 MYC-driven lymphomas18,20 and immunodeﬁciency or
lymphoproliferative states.19 It is interesting to note that while this
effect, in MYC-driven lymphoma at least, is primarily mediated by
miR-19 family members (miR-19a/b), we have identiﬁed principally
a miR-17 family- (miR-17, miR-20a/b, miR-106a/b and miR-93) and
miR-18 family(miR-18a/b)-driven effect in BCR-ABL-positive ALL on
BCL2, indicating differences in pro- and anti-apoptotic functions of
miR-17B92 between the various cellular contexts.
In keeping with the phenotype described for the TonB model,
an unbiased global proteomic approach identiﬁed several
apoptosis-related proteins as miR-17B19b targets. As targeting
the anti-apoptotic pathway offered a logical therapeutic
approach, we chose to focus our validation studies on the
well-characterized anti-apoptotic protein BCL2. BCL2, an inhibitor
of the mitochondrial apoptotic pathway, is the founding member
of a large family of BH-domain containing proteins with pro- and
anti-apoptotic activities upstream of caspase-activation.34,35
Notably, Bcl2 induction has previously been shown to be
important for prevention of apoptosis in BCR-ABL expressing BaF3
cells.36 Our data suggest that downregulation of miR-17B92 may be
an important mediator of this effect. This may also explain why
overexpression of the cluster has little phenotypic effect in BCR-ABL-
negative ALL cells, where Bcl2 expression may be less critical.
Small molecule BH3-domain mimetica, notably ABT-73737 and
its orally bioavailable analogue ABT-263 (Navitoclax)38 have
been designed to inhibit BCL2.39 BCL2 inhibition has
demonstrated efﬁcacy in pre-clinical and early phase clinical
trials in small-cell-lung cancer,40 myeloma41 and high-risk B cell
Figure 8. ABT-737 impairs expansion of human primary BCR-ABLþ ALL cells in vivo. (a) NSG mice were transplanted with luciferase-expressing
L4951 blasts and treated with ABT-737 (50mg/kg/day) or vehicle control for 6 weeks (black bar) following successful engraftment. Graph shows
average of total flux from whole mouse at each measurement point, n¼ 7 mice per group. (b) Images of representative mice from ABT-737 treated
and control groups showing expansion of luciferase-expressing transduced blasts over time. Mice during treatment period (weeks 0–6) and after
treatment (weeks 9–18) are shown on different radiance scales to avoid image saturation. Supplementary Figure 6 shows all the images on the
same scale. (c) Kaplan–Meier survival curves for mice transplanted with L4951 blasts treated with ABT-737 (50mg/kg/day) or vehicle control. Black
bar¼ treatment period. Median survival 151 days (control), 190 days (ABT-737 treated), P¼ 0.0004.
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non-Hodgkin lymphoma.42 Furthermore, dramatic responses have
been seen in chronic lymphocytic leukaemia,27 where
development of ABT-263 has produced a potent agent, ABT-199,
which avoids the problem of thrombocytopenia seen with earlier
agents.43 We investigated the efﬁcacy of the ﬁrst high-afﬁnity
BCL2 inhibitor, ABT-737, and have demonstrated a BCR-ABL
speciﬁc effect in ALL in vitro. Furthermore, ABT-737 appeared to
be more potent than imatinib in this setting, suggesting that BCL2
inhibition has the potential to improve on current therapeutic
regimens. In order to pre-clinically investigate the effect of
potential therapies in ALL in a supportive microenvironment, we
have developed a real-time murine xenograft model of patient-
derived BCR-ABL-positive ALL.24 Six weeks of treatment with ABT-
737 led to a signiﬁcantly slower rate of leukaemic progression and
associated prolonged survival compared with vehicle treated
mice. The increase in dissemination of luciferase-expressing
tumour cells following cessation of ABT-737 treatment suggests
that even better outcomes could be achieved with on-going
treatment. Furthermore, there was no effect on the heart in ABT-
737 treated mice (data not shown) or on BCL2 expression in
cardiomyocytes in vitro (Supplementary Figure 7). These results
demonstrate both the in vivo efﬁcacy of BCL2 inhibition in
BCR-ABL-positive ALL, as well as the potential for our approach in
pre-clinical disease modelling.
Our data indicate a selective advantage for low miR-17B92
expression in primary BCR-ABL-positive ALL cells. Since these
miRNAs regulate expression of BCL2 and other apoptosis
regulators, the data demonstrate the crucial balance between
proliferative signals and apoptosis in BCR-ABL-positive ALL. Our
results demonstrate that BCR-ABL expression may result not only
in a proliferative state, but also in one which is primed for
apoptosis and therefore reliant on upregulation of BCL2. This
makes therapeutic targeting of this key anti-apoptotic molecule a
logical and attractive option and may provide a therapeutic
window relative to normal tissues. Inhibition of BCL2 and BCR-ABL
in BCR-ABL-positive ALL cells resulted in different kinetics of cell
death, turn-over of BCL2 protein and induction of miR-17B92
expression. We found that ABT-737 treatment led to a decrease in
BCL2 protein levels and an increase in miR-17B92 miRNA
expression in a BCR-ABL-dependent manner, suggesting that
BCL2 inhibition results in the perturbation of a complex signalling
network. This apparent positive feedback loop may act to
augment the effects of pharmacological BCL2 inhibition.
In summary, we have sought to identify potential therapeutic
targets in BCR-ABL-positive ALL by validating targets of a miRNA
cluster showing downregulated expression and important survival
function in this disease. Having validated the anti-apoptotic
protein BCL2 as a miR-17B92 target, we have demonstrated the
direct control of BCL2 expression by miRB17 and miRB18 family
members by the canonical RNAi effector protein AGO2. Finally, we
have demonstrated pre-clinical efﬁcacy of the BCL2 inhibitor,
ABT-737, both in an in vitro setting and using an in vivo model of
human BCR-ABL-positive ALL. We suggest that BCL2 inhibition
should be considered for early phase clinical testing in
BCR-ABL-positive ALL as a new strategy either to improve current
standard curative treatments or long-term disease control.
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